Cargando…
Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction
Close examination of the initial results of cardiovascular cell therapy clinical trials indicates the importance of patient-specific differences on outcomes and the need to optimize or customize cell therapies. The fields of regenerative medicine and cell therapy have transitioned from using heterog...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266164/ https://www.ncbi.nlm.nih.gov/pubmed/35805175 http://dx.doi.org/10.3390/cells11132092 |
_version_ | 1784743396336730112 |
---|---|
author | Morrissey, Jacquelynn Mesquita, Fernanda C. P. Chacon-Alberty, Lourdes Hochman-Mendez, Camila |
author_facet | Morrissey, Jacquelynn Mesquita, Fernanda C. P. Chacon-Alberty, Lourdes Hochman-Mendez, Camila |
author_sort | Morrissey, Jacquelynn |
collection | PubMed |
description | Close examination of the initial results of cardiovascular cell therapy clinical trials indicates the importance of patient-specific differences on outcomes and the need to optimize or customize cell therapies. The fields of regenerative medicine and cell therapy have transitioned from using heterogeneous bone marrow mononuclear cells (BMMNCs) to mesenchymal stromal cells (MSCs), which are believed to elicit benefits through paracrine activity. Here, we examined MSCs from the BMMNCs of heart failure patients enrolled in the FOCUS-CCTRN trial. We sought to identify differences in MSCs between patients who improved and those who declined in heart function, regardless of treatment received. Although we did not observe differences in the cell profile of MSCs between groups, we did find significant differences in the MSC secretome profile between patients who improved or declined. We conclude that “mining” the MSC secretome may provide clues to better understand the impact of patient characteristics on outcomes after cell therapy and this knowledge can inform future cell therapy trials. |
format | Online Article Text |
id | pubmed-9266164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92661642022-07-09 Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction Morrissey, Jacquelynn Mesquita, Fernanda C. P. Chacon-Alberty, Lourdes Hochman-Mendez, Camila Cells Opinion Close examination of the initial results of cardiovascular cell therapy clinical trials indicates the importance of patient-specific differences on outcomes and the need to optimize or customize cell therapies. The fields of regenerative medicine and cell therapy have transitioned from using heterogeneous bone marrow mononuclear cells (BMMNCs) to mesenchymal stromal cells (MSCs), which are believed to elicit benefits through paracrine activity. Here, we examined MSCs from the BMMNCs of heart failure patients enrolled in the FOCUS-CCTRN trial. We sought to identify differences in MSCs between patients who improved and those who declined in heart function, regardless of treatment received. Although we did not observe differences in the cell profile of MSCs between groups, we did find significant differences in the MSC secretome profile between patients who improved or declined. We conclude that “mining” the MSC secretome may provide clues to better understand the impact of patient characteristics on outcomes after cell therapy and this knowledge can inform future cell therapy trials. MDPI 2022-06-30 /pmc/articles/PMC9266164/ /pubmed/35805175 http://dx.doi.org/10.3390/cells11132092 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Opinion Morrissey, Jacquelynn Mesquita, Fernanda C. P. Chacon-Alberty, Lourdes Hochman-Mendez, Camila Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction |
title | Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction |
title_full | Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction |
title_fullStr | Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction |
title_full_unstemmed | Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction |
title_short | Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction |
title_sort | mining the mesenchymal stromal cell secretome in patients with chronic left ventricular dysfunction |
topic | Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266164/ https://www.ncbi.nlm.nih.gov/pubmed/35805175 http://dx.doi.org/10.3390/cells11132092 |
work_keys_str_mv | AT morrisseyjacquelynn miningthemesenchymalstromalcellsecretomeinpatientswithchronicleftventriculardysfunction AT mesquitafernandacp miningthemesenchymalstromalcellsecretomeinpatientswithchronicleftventriculardysfunction AT chaconalbertylourdes miningthemesenchymalstromalcellsecretomeinpatientswithchronicleftventriculardysfunction AT hochmanmendezcamila miningthemesenchymalstromalcellsecretomeinpatientswithchronicleftventriculardysfunction |